Superficial Punctate Keratitis Treatment Global Market Report 2025

The superficial punctate keratitis treatment market size has grown strongly in recent years. It will grow from $4.91 billion in 2024 to $5.25 billion in 2025 at a compound annual growth rate (CAGR) of 6.9%. The growth during the historic period can be credited to the rising prevalence of ocular surface disorders, increased awareness of eye health, growing demand for topical treatments, an expanding geriatric population, improvements in healthcare infrastructure, and heightened R&D activities in ophthalmology.

The superficial punctate keratitis treatment market size is expected to see strong growth in the next few years. It will grow to $6.79 billion in 2029 at a compound annual growth rate (CAGR) of 6.7%. The growth during the forecast period can be credited to the increasing prevalence of dry eye syndrome, rising use of contact lenses, greater awareness of eye health, expanding healthcare infrastructure in emerging economies, and a growing focus on personalized treatments. Key trends include advancements in drug formulations for improved corneal healing, the development of targeted biologics, innovations in ocular lubricants and artificial tears, integration of nanotechnology for drug delivery, progress in minimally invasive surgical techniques, the use of regenerative therapies such as stem cells, and the adoption of digital diagnostics for personalized treatment plans.

The increasing prevalence of eye diseases is expected to drive the growth of the superficial punctate keratitis treatment market. Eye diseases encompass a range of conditions affecting vision and eye health, including infections, degenerative disorders, and structural abnormalities. The rising incidence of these conditions is attributed to aging populations, prolonged screen exposure, diabetes, and environmental factors such as pollution and UV radiation. Treatments for superficial punctate keratitis, including lubricating eye drops, antibiotics, and anti-inflammatory medications, help alleviate pain, reduce inflammation, and promote healing for corneal surface damage. For example, in May 2024, the Office for Health Improvement and Disparities, a UK-based government agency, reported that England recorded over 8.9 million vision outpatient attendances in the financial year ending 2023, with a rate of 15,362 per 100,000 population, up from 14,613 in the previous year. As a result, the increasing prevalence of eye diseases is fueling the demand for superficial punctate keratitis treatments.

Leading companies in the superficial punctate keratitis treatment market are focusing on innovative products, such as advanced eye drops, to address inflammation and provide effective, non-invasive treatment options. Eye drops, formulated as liquid solutions, are widely used to manage irritation, dryness, inflammation, and infections. For instance, in May 2023, Entod Pharmaceuticals, an India-based pharmaceutical company, introduced CYCLOTEARS eye drops in India and other global markets for individuals suffering from inflammatory dry eye disease (DED). This product is the first dry eye therapy worldwide to incorporate the company’s self-emulsifying drug delivery system (SEDDS) technology, a breakthrough in treating eye inflammation. This cutting-edge formulation enhances drug absorption and efficacy, providing improved relief for patients.

In July 2024, Bausch + Lomb Corporation, a Canada-based eye health company, acquired Trukera Medical for an undisclosed amount. This acquisition is intended to expand Bausch + Lomb’s surgical presence in the U.S. and strengthen its capabilities in dry eye management by integrating Trukera’s scoutPro device, a valuable tool for pre-surgical assessment and optimization. Trukera Medical is a US-based company specializing in diagnostic tools, including the scoutPro, designed for assessing corneal health and diagnosing dry eye disease.

Major players in the superficial punctate keratitis treatment market are Pfizer Inc., Johnson & Johnson, AbbVie Inc., Merck & Co. Inc., Bayer AG, Sanofi S.A., Novartis AG, GlaxoSmithKline plc (GSK), Alcon Inc., Bausch + Lomb Corporation, Sun Pharmaceutical Industries Ltd., Mallinckrodt Pharmaceuticals plc, Santen Pharmaceutical Co. Ltd., Prestige Consumer Healthcare Inc., Dompé Farmaceutici S.p.A., OASIS Medical Inc., Bruschettini S.r.l., Allergan plc, CONTACARE Ophthalmics Pvt. Ltd., and Prevego Healthcare Ltd.

North America was the largest region in the superficial punctate keratitis treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in superficial punctate keratitis treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the superficial punctate keratitis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Superficial punctate keratitis (SPK) treatment involves managing corneal irritation caused by factors such as dry eyes, infections, or environmental stress. Treatment options include lubricating eye drops, anti-inflammatory medications, and addressing underlying conditions to promote healing. The primary goals of treatment are to relieve discomfort, reduce inflammation, and restore corneal health.

The key product categories in the superficial punctate keratitis treatment market include pharmacological treatments, surgical procedures, minimally invasive interventions, digital health solutions (such as telemedicine and mobile applications), and other treatment options. Pharmacological treatments consist of medications such as antibiotics, antifungals, and anti-inflammatory eye drops that help combat infections and reduce inflammation. These treatments are distributed through hospital pharmacies, retail pharmacies, and online pharmacies and are utilized by various end-users, including hospitals, ophthalmology clinics, home care settings, and ambulatory surgical centers.

The superficial punctate keratitis treatment market research report is one of a series of new reports that provides superficial punctate keratitis treatment market statistics, including the superficial punctate keratitis treatment industry's global market size, regional shares, competitors with a superficial punctate keratitis treatment market share, detailed superficial punctate keratitis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the superficial punctate keratitis treatment industry. This superficial punctate keratitis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The superficial punctate keratitis treatment market consists of revenues earned by entities through services such as diagnosis and consultation, prescription services, specialized therapeutic procedures, post-treatment monitoring and follow-up, patient education, and preventive care. The market value includes the value of related goods sold by the service provider or included within the service offering. The superficial punctate keratitis treatment market also includes sales of lubricating eye drops and artificial tears, topical medications, contact lenses, diagnostic tools, UV protection glasses, and shields. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.